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Protein modelling
Protein structure homology modelling was performed using the SWISS-MODEL workspace (Biasini, et al 2014) . The SWISS-MODEL template library (SMTL version 2017-02-01, PDB release 2017-01-26) was searched with Blast and HHBlits for evolutionary related structures matching the target sequence. Results are shown using the myosin 2 heavy chain template (amino acids 1-959). There is no model from amino acid 960 to 1960 due to the lack of homology with any other protein.
DNA extraction and Sanger sequencing
Peripheral venous blood was collected at over 100 hospitals by Hematologists with an interest in inherited BPDs and sent to the Cambridge Translational GenOmics (CATGO) laboratory in Cambridge (UK) in EDTA tubes. Genomic DNA was extracted and quantified using PicoGreen (ThermoFisher Scientific Inc., MA, USA). All variants described in this paper were confirmed by Sanger sequencing. Primers were designed using PRIMER3 and the amplification carried out in a GeneAmp PCR System 9700 using 10ng DNA.
Amplicons were purified by using QIAGEN (QIAGEN, Venlo, The Netherlands) columns and sent for Sanger sequencing to Source BioScience (Source BioScience, UK). Ethics authorities and approval numbers are provided in Table S1 .
Immunofluorescence
Immunofluorescence analysis was performed by two independent centres. In center 1, blood smears were fixed and permeabilized with ice cold acetone for 3 minutes, blocked with 1% BSA for 1 hour and incubated with a rabbit-anti human NMMHCIIA antibody (Sigma Aldrich, M8064) and an Alexa-Fluor ® 488 conjugated secondary antibody (Life Technologies). Nuclei were stained with Hoechst. Specimens were mounted with the ProLong Antifade medium (Molecular Probes) and analyzed at room temperature by a Carl Zeiss Axio Observer.A1 fluorescence microscope (Carl Zeiss Inc, Oberkochen,
Germany).
In centre 2, blood smears were fixed with acetone for 2 min and blocked with goat serum donor herd (Sigma G-6767, St. Louis, US) followed by staining with an anti-NMMHCIIA Pinhole was set to 67.9 µm (1 Airy Unit) and emission was collected by PMT 2 (508nm -540nm). Image processing and analysis was performed on Bitplane Imaris version 7.6.5
(Bitplane, Switzerland).
Gene expression analysis
BLUEPRINT RNA sequencing data (http://dcc.blueprint-epigenome.eu/#/datasets) were downloaded from EGA and processed as follow:
Trim Galore 0.3.7 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) with parameters "-q 15 -s 3 --length 30 -e 0.05" was used to trim PCR and sequencing adapters off. Trimmed reads were then aligned to the Ensembl v.70 human transcriptome using Bowtie 1.0.1 (PMID: 19261174) with parameters "-a --best --strata -S -m 100 -X 500 --chunkmbs 256 --nofw --fr". MMSEQ 1.0.8a with default parameters 2,3 was used to quantify (gene and) transcript expression. Mmdiff with parameters "-fixalpha -p 0 -uhfrac 1.0" was used to summarise and normalize (gene and) transcript expression for cell type. This variant is present in one non-BPD patient and absent in the affected mother. Platelet count 217x10 9 /L. Table S6 . Bleeding score. Patients were classified according to the 12 major symptoms within the MCMDM-1 VWD Bleeding Assessment Tool with scores from -1 to 4. Total bleeding score are shown for females and males. Bleeding score is considered normal if less than 3 and 5 for males and females, respectively.
Sequencing and bioinformatics pipeline
Bleeding Phenotype score -1 1 2 3 4
CNS bleeding
Cutaneous 5, 6*, 7, 10, 12, 18, 21, 22, 23, 25*, 28, 41, 43, 44, 46*, 47, 48, 49 1, 9, 16, 37, 38 Epistaxis 1, 18, 22, 24, 26, 28, 33, 40, 41, 42, 43, 44, 46*, 50 14, 15, 16, 21, 30, 47 From minor wounds 1, 18, 22, 30, 43, 44, 45 Tooth extraction 13, 14, 15, 16, 17, 21, 24, 37 8, 30, 40, 44, 45 34, 38 Total Bleeding Score BS=0 BS 1-5 BS≧6 Female cases 11, 13, 27, 29, 35, 36 4, 8, 9, 12, 14, 15, 17, 18, 23, 25, 33, 37, 41, 42, 43, 44, 45, 50 1, 16, 21, 34, 40, 47 General Bleeding Severity BS=0 BS 1-3 BS≧4
Male cases 3, 19, 31, 32, 39 2, 5, 6, 7, 10, 22, 24, 26, 28, 46, 48, 49 20**, 30**, 38 * 6, 8, 25, 45, 46 are patients with no calculated bleeding score. The bleeding score has been assigned according to the clinical synopsis provided. **prolonged bleeding after surgery 
